DIAGNOSTIC VALUE OF LTB4 AND IL-6 DETERMINATION IN PATIENTS WITH HYPERTENSION, OVERWEIGHT AND/OR OBESITY AND IN COMBINATION WITH CORONAVIRUS DISEASE
DOI:
https://doi.org/10.32782/2786-9067-2024-28-8Keywords:
arterial hypertension, obesity, COVID-19, LTB4, IL-6Abstract
Arterial hypertension (AH) is the most common comorbidity among patients with coronavirus disease (COVID-19) and, regardless of other risk factors, worsens its course, which is apparently associated with immune activation and inflammation in the presence of AH and overweight and/or obesity. The aim of the study was to investigate the content of leukotriene B4 (LTB4) and interleukin 6 (IL-6) in patients with AH, overweight and/or obesity and in combination with COVID-19. Materials and methods. We examined 84 patients:group 1 - 40 patients with AH, overweight and/or obesity, group 2 - 44 patients with AH, overweight and/or obesity and COVID-19 with interstitial lung damage. The control group consisted of 20 practically healthy volunteers. All patients underwent anthropometric, general clinical, laboratory, instrumental studies, and additionally determined the content of LTB4 and IL-6 in serum by enzyme-linked immunosorbent assay using identical protocols with LTB4 ELISA Kit and Human IL-6 SimpleStep ELISA Kit. Results. Patients with AH and overweight and/or obesity and COVID-19 had significantly higher LTB4 values 995 (767.5; 1645) pg/ml than in the group of patients with AH and overweight and/or obesity – 658.5 (433.5;858.75 pg/ml. Meanwhile, there was a significant growth of IL-6 in patients with AH and overweight and/or obesity (7.36±0.79 pg/ml) and in the combination of AH, overweight and/or obesity with COVID-19 (30.94±3.19 pg/ml). Conclusions. The course of AH in patients with overweight and/or obesity is accompanied by elevated values of LTB4 and IL-6, which is a consequence of chronic inflammation. Increased levels of LTB4 and IL-6 in patients with AH, overweight and/or obesity, and COVID-19 are likely to be a sign of a cytokine storm, with LTB4 levels asa neutrophil chemoattractant indicating a more serious course of this comorbid pathology. Given the important role of LTB4 and IL-6 in the pathogenesis of COVID-19, they can be considered as pharmacological targets to reduce the risk of severe coronavirus disease and improve the prognosis in patients with AH, overweight and/or obesity.
References
Самчук О.О., Склярова О.Є., Бочар О.М., Магійович С.Р., Кобилінська Л.І., Бочар В.Т., Скляров Є.Я. Рівень ІЛ-6 у пацієнтів з артеріальною гіпертензією у поєднанні з коронавірусною хворобою. Експериментальна та клінічна фізіологія і біохімія. 2022. Т. 94, № 1-2. С. 38-43. DOI: https://doi.org/10.25040/ecpb2022.01-02.038.
Склярова О.Є., Покровська Н.К., Грушка О.І., Скляров Є.Я. Рівень лейкотрієну В4 у хворих на артеріальну гіпертензію та коронавірусну хворобу. Медична наука України. 2022. Т. 18, № 1. С. 3-7. DOI: https://doi.org/10.32345/2664-4738.1.2022.01.
Akbar A.N., Gilroy D.W. Aging immunity may exacerbate COVID-19. Science. 2020. Vol. 369, № 6501. Р. 256-257. DOI: https://doi.org/10.1126/science.abb0762.
Citron F., Perelli L., Deem A.K., Genovese G., Viale A. Leukotrienes, a potential target for Covid-19. Prostaglandins Leukot Essent Fatty Acids. 2020. Vol. 161:102174. DOI: https://doi.org/10.1016/j.plefa.2020.102174.
Dufrusine B., Valentinuzzi S., Bibbò S. et al. Iron Dyshomeostasis in COVID-19: Biomarkers Reveal a Functional Link to 5-Lipoxygenase Activation. International Journal of Molecular Sciences. 2023. Vol. 24, № 1. Р. 15. DOI: https://doi.org/10.3390/ijms24010015.
Grasselli G., Zangrillo A., Zanella A., et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy JAMA. 2020. Vol. 323, № 16. Р. 1574-1581. DOI: https://doi.org/10.1001/jama.2020.5394.
Guan W.J., Ni Z.Y., Hu Y. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020. Vol. 382, № 18. Р. 1708-1720. DOI: https://doi.org/10.1056/NEJMoa2002032.
He R., Chen Y., Cai Q. The role of the LTB4-BLT1 axis in health and disease Pharmacol Res. 2020. Vol. 158:104857. DOI: https://doi.org/10.1016/j.phrs.2020.104857.
Herold T., Jurinovic V., Arnreich C. et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020. Vol. 146, № 1. Р. 128–36.e4. DOI: https://doi.org/10.1016/j.jaci.2020.05.008.
Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021. Vol. 33, № 3. Р. 127-148. DOI: https://doi.org/10.1093/intimm/dxaa078.
Liu T., Zhang J., Yang Y. et al. The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. EMBO Mol Med. 2020. Vol. 12, № 7. e12421. DOI: https://doi.org/10.15252/emmm.202012421.
Oluboyo A.O., Okoro C.M., Ekpo V.E., Oluboyo B.O. Assessment of interleukins 1 and 6 in hypertensive subjects. International Journal of Biological and Chemical Sciences. 2019. Vol. 13, № 6. Р. 2513-2520. DOI: https://doi.org/10.4314/ijbcs.v13i6.7.
Sasaki F., Yokomizo T. The leukotriene receptors as therapeutic targets of inflammatory diseases, International Immunology, 2019. Vol. 31, Issue 9. P. 607–615. DOI: https://doi.org/10.1093/intimm/dxz044.
Wang W., Liu X., Wu S. et al. Definition and Risks of Cytokine Release Syndrome in 11 Critically Ill COVID-19 Patients With Pneumonia: Analysis of Disease Characteristics. J Infect Dis. 2020. Vol. 222, № 9. Р. 1444–1451. DOI: https://doi.org/10.1093/infdis/jiaa387.
Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020. Vol. 395, № 10229. Р. 1054-1062. DOI: https://doi.org/10.1016/S0140-6736(20)30566-3.
Zhu Z., Cai T., Fan L. et al. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. Int J Infect Dis. 2020. Vol. 95. P. 332–339. DOI: https://doi.org/10.1016/j.ijid.2020.04.041.
